查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2030075

靜脈注射鐵劑市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球靜脈注射鐵劑產品市場預計將從 2025 年的 25.5 億美元成長到 2031 年的 35.7 億美元，複合年成長率為 5.77%。

靜脈注射鐵劑是治療方法，旨在治療缺鐵和缺鐵性貧血。它尤其適用於無法口服鐵劑的患者、吸收不良的患者或需要快速補充鐵劑的患者。市場成長的主要促進因素是全球範圍內與慢性腎臟病、發炎性腸道疾病和癌症相關的貧血盛行率不斷上升。此外，全球人口老化加劇了缺鐵的風險，進一步增加了靜脈注射鐵劑的需求。例如，世界衛生組織（WHO）發布的《2025年全球貧血預測》報告顯示，到2023年，15至49歲女性中將有30.7%患有貧血，這充分說明了貧血患者的數量之多。

市場概覽
預測期 2027-2031
市場規模：2025年 25.5億美元
市場規模：2031年 35.7億美元
複合年成長率：2026-2031年 5.77%
成長最快的細分市場 聚葡萄糖鐵
最大的市場 北美洲

儘管存在這些成長要素，但市場擴張的主要障礙是研發和生產這些先進靜脈輸液治療方法的高昂成本。這種經濟壁壘可能會限制其在各種醫療保健系統中的廣泛應用。

市場促進因素

全球靜脈注射鐵劑市場的主要驅動力是口服鐵劑療法的不足和耐受性差。許多患者飽受胃腸道副作用的困擾，常常導致他們無法繼續甚至停止口服治療。此外，慢性腎臟病、發炎性腸道疾病以及既往的減重手術等疾病會顯著限制口服鐵劑的吸收，使其失效。重度貧血和急性情況下對快速補充鐵劑的迫切需求也增加了對靜脈注射的需求。美國血液學會（ASH）2025年12月年會暨展覽會的數據顯示，在多學科共同努力下，孕婦靜脈鐵劑的使用量在一年內成長了20倍，這印證了上述轉變。這表明，當口服治療無效時，人們對更有效的替代療法有強烈的需求。

同時，由於靜脈鐵劑製劑的不斷改進，市場正在擴張，這些改進提高了患者的便利性，加快了輸注速度，並提升了安全性。製藥公司正致力於開發具有更低免疫抗原性風險和最佳化藥物動力學的先進產品，從而增加單次給藥劑量並減少治療頻率。這些突破性進展正在解決以往存在的輸注時間過長和過敏反應等問題。例如，CSL 2025年8月的年度報告顯示，開發平臺十分強勁，CSL Vifor正準備在腎臟疾病和鐵劑供應領域推出30多種產品。根據世界衛生組織（WHO）發布的《2025年全球貧血預測》，到2023年，15至49歲孕婦中將有35.5%患有貧血，因此，優先推廣這些改進的治療方法對於對抗普遍存在的缺鐵問題仍然至關重要。

市場挑戰

全球靜脈注射鐵劑市場擴張面臨的主要障礙之一是研發和生產這些尖端治療方法所需的高昂成本。這些複雜的藥物在其生命週期的每個階段都需要巨額投資，從早期研究和全面的臨床試驗，到嚴格的監管核准和高度專業化的生產技術。最終，這些高額的資金需求導致最終上市產品的價格虛高。

如此高昂的價格嚴重限制了靜脈注射鐵劑的廣泛應用，尤其是在預算緊張或報銷限制嚴格的醫療機構中。國際藥品製造商協會聯合會（IFPMA）預測，到2025年，全球醫藥品研究開發費用將超過2,000億美元，反映了產業投資規模推高了最終藥品價格。因此，許多患者無法獲得這些關鍵治療，儘管全球缺鐵和相關貧血的發生率持續上升，但這直接阻礙了整體市場的成長潛力。

市場趨勢

全球靜脈鐵劑市場的一個顯著趨勢是居家和門診治療的普及。這一趨勢主要源於患者對更便捷治療、減少就醫次數以及透過分散式醫療降低醫療成本的日益成長的需求。此外，攜帶式輸液技術的進步以及能夠快速、高劑量給藥的製劑的研發也推動了這一轉變，使更多患者能夠在傳統醫療機構之外接受鐵劑補充治療。

同時，產業另一大趨勢是價格親民的非專利靜脈注射鐵劑和生物相似藥的日益普及。這些具成本效益替代品的出現加劇了市場競爭，最終將降低藥物成本，並使更多患者能夠獲得治療。 Fierce Pharma在2026年2月的一份報告中強調了這一影響：產業領導者CSL在2026會計年度累計11億美元的減損損失，部分原因是其鐵劑補充療法Venofer面臨學名藥的激烈競爭。對於那些力求在不影響患者獲得必要治療的前提下控制藥物成本的醫療網路而言，這種競爭動態至關重要。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球靜脈注射鐵劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品成分（聚葡萄糖鐵、葡萄糖酸鐵、蔗糖鐵、Ferric carboxymaltose、異麥芽糖苷鐵 1000、Ferumoxytol）
    • 依應用情況（吸收不良症候群、發炎性疾病、切除術/減重手術、貧血、奧西爾-韋伯-倫杜氏症、血管畸形、懷孕、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美靜脈注射鐵劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲靜脈注射鐵劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區靜脈注射鐵劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲靜脈注射鐵劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲靜脈注射鐵劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球靜脈注射鐵劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AMAG pharmaceuticals, Inc.
  • Vifor Pharma Management Ltd.
  • Daiichi Sankyo Company, Limited
  • Rockwell Medical Inc.
  • Allergan PLC
  • Pfizer Inc.
  • Nippon Shinyaku Co.
  • Novartis International AG
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5093

The Global Intravenous Iron Drugs Market is anticipated to expand from USD 2.55 billion in 2025 to USD 3.57 billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.77%. Administered directly into the bloodstream, intravenous (IV) iron therapies are designed to combat iron deficiency and iron deficiency anemia, especially for patients who cannot tolerate oral iron, suffer from malabsorption, or need rapid iron restoration. Market growth is primarily fueled by the rising worldwide incidence of chronic kidney disease, inflammatory bowel disease, and anemias linked to cancer. Furthermore, an aging global population more prone to iron deficiencies amplifies this need. Highlighting the substantial patient base, the World Health Organization's Global Anaemia estimates (2025 Edition) reported that 30.7% of women between 15 and 49 years old experienced anemia in 2023.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.55 Billion
Market Size 2031USD 3.57 Billion
CAGR 2026-20315.77%
Fastest Growing SegmentIron Dextran
Largest MarketNorth America

Despite these growth drivers, a major obstacle hindering market expansion is the steep expense tied to the development and production of these sophisticated intravenous treatments. This financial barrier could restrict their broad implementation across various healthcare systems.

Market Driver

The Global intravenous iron drugs market is primarily propelled by the drawbacks and poor tolerability of oral iron treatments. Because many individuals suffer from gastrointestinal side effects, they often fail to adhere to or completely abandon oral therapies. Additionally, medical conditions such as chronic kidney disease, inflammatory bowel disease, and previous bariatric surgeries can severely limit oral iron absorption, rendering it useless. The urgent demand for quick iron restoration in severe anemia or acute situations also drives the need for IV delivery. Highlighting this shift, data from the December 2025 American Society of Hematology (ASH) Annual Meeting and Exposition revealed that a multidisciplinary initiative resulted in a 20-fold increase in IV iron infusions for pregnant women over a single year, underlining the strong preference for more effective alternatives when oral treatments fail.

Simultaneously, the market is growing due to continuous improvements in IV iron formulations that deliver greater patient convenience, quicker infusion rates, and enhanced safety. Drug manufacturers are diligently creating advanced products featuring lowered immunogenic risks and refined pharmacokinetics, which allow for larger single doses and less frequent treatments. Such breakthroughs resolve past issues like lengthy infusion times and allergic reactions. Illustrating this progress, CSL's August 2025 Annual Report noted that CSL Vifor was gearing up for more than 30 product rollouts within its nephrology and iron sectors, indicating a robust developmental pipeline. Prioritizing these enhanced therapies remains essential to combatting widespread iron deficiency, as the WHO's 2025 Global Anaemia estimates indicated that 35.5% of pregnant women aged 15 to 49 were anemic in 2023.

Market Challenge

A major hurdle slowing the expansion of the global intravenous iron drugs market is the steep expense involved in the creation and production of these modern therapies. These complex medications require massive financial investments at every stage of their lifecycle, spanning early-stage research and comprehensive clinical trials to rigorous regulatory clearances and highly specialized manufacturing techniques. Ultimately, these heavy financial requirements result in higher prices for the final commercial products.

Such premium pricing severely restricts the broad utilization of IV iron medications, especially in healthcare networks facing tight budgets or strict reimbursement limitations. Demonstrating the scale of industry investments that drive up final drug prices, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) forecasts that worldwide pharmaceutical research and development spending will surpass USD 200 billion in 2025. As a result, a large number of patients are denied access to these vital treatments, which directly suppresses the market's overall growth potential even as the worldwide incidence of iron deficiency and associated anemias continues to climb.

Market Trends

A prominent trend within the global intravenous iron drugs market is the transition toward administering treatments in home-based and outpatient settings. This movement is largely motivated by a growing patient desire for convenience, fewer hospital trips, and the possibility of decreasing medical expenses through decentralized healthcare. The shift is additionally supported by progress in portable infusion technology and the creation of drug formulations that permit rapid, high-dose administrations, allowing a greater number of patients to undergo iron restoration away from conventional clinical facilities.

At the same time, the rising prevalence of affordable generic IV iron options and biosimilars marks another major industry development. The availability of these budget-friendly substitutes heightens market competition, which ultimately drives down medication costs and broadens therapeutic access for a larger demographic. Highlighting this impact, Fierce Pharma reported in February 2026 that industry leader CSL recorded $1.1 billion in asset impairments for fiscal year 2026, driven in part by escalating generic rivalry against its Venofer iron replacement therapy. Such competitive dynamics are vital for healthcare networks striving to control drug spending without compromising patient access to crucial therapies.

Key Market Players

  • AMAG pharmaceuticals, Inc.
  • Vifor Pharma Management Ltd.
  • Daiichi Sankyo Company, Limited
  • Rockwell Medical Inc.
  • Allergan PLC
  • Pfizer Inc.
  • Nippon Shinyaku Co.
  • Novartis International AG
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.

Report Scope

In this report, the Global Intravenous Iron Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intravenous Iron Drugs Market, By Product

  • Iron Dextran
  • Ferric Gluconate
  • Iron Sucrose
  • Ferric Carboxymaltos
  • Iron Isomaltoside 1000
  • Ferumoxytol

Intravenous Iron Drugs Market, By Application

  • Intestinal Malabsorption Syndromes
  • Inflammatory Diseases
  • Gastrectomy/Bariatric Surgery
  • Anemia
  • Osier-Weber-Rendu Disease
  • Angiodysplasia
  • Pregnancy
  • Others

Intravenous Iron Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Iron Drugs Market.

Available Customizations:

Global Intravenous Iron Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Intravenous Iron Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxymaltos, Iron Isomaltoside 1000, Ferumoxytol)
    • 5.2.2. By Application (Intestinal Malabsorption Syndromes, Inflammatory Diseases, Gastrectomy/Bariatric Surgery, Anemia, Osier-Weber-Rendu Disease, Angiodysplasia, Pregnancy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Intravenous Iron Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Intravenous Iron Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Intravenous Iron Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Intravenous Iron Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Intravenous Iron Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Intravenous Iron Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Intravenous Iron Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Intravenous Iron Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Intravenous Iron Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Intravenous Iron Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Intravenous Iron Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Intravenous Iron Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Intravenous Iron Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Intravenous Iron Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Intravenous Iron Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Intravenous Iron Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Intravenous Iron Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Intravenous Iron Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Intravenous Iron Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Intravenous Iron Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Intravenous Iron Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Intravenous Iron Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Intravenous Iron Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Intravenous Iron Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Intravenous Iron Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AMAG pharmaceuticals, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Vifor Pharma Management Ltd.
  • 15.3. Daiichi Sankyo Company, Limited
  • 15.4. Rockwell Medical Inc.
  • 15.5. Allergan PLC
  • 15.6. Pfizer Inc.
  • 15.7. Nippon Shinyaku Co.
  • 15.8. Novartis International AG
  • 15.9. Takeda Pharmaceutical Company Limited
  • 15.10. Bausch Health Companies Inc.

16. Strategic Recommendations

17. About Us & Disclaimer